You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ph CML-CP

Showing 51 - 75 of 3,666
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Myelogenous Leukemia Trial in Canada, United States (Nilotinib)

Completed
Has Results
  • Chronic Myelogenous Leukemia
  • Fayetteville, Arkansas
  • +22 more
Jun 29, 2021

Chronic Myeloid Leukemia, Ph+ Acute Lymphoblastic Leukemia Trial in Worldwide (Ponatinib)

Completed
Has Results
  • Chronic Myeloid Leukemia
  • Ph+ Acute Lymphoblastic Leukemia
  • St Leonards, New South Wales, Australia
  • +41 more
Jan 18, 2021

CML, Chronic Phase Trial in Harbin (Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg))

Recruiting
  • CML, Chronic Phase
  • Flumatinib mesylate tablets (400mg)
  • Flumatinib mesylate tablets (600mg)
  • Harbin, Hei Longjiang, China
    Institute of Hematology and Oncology, Harbin The First Hospital
Apr 28, 2022

Chronic Myelogenous Leukemia Trial in Worldwide (Asciminib, Bosutinib)

Active, not recruiting
Has Results
  • Chronic Myelogenous Leukemia
  • Chicago, Illinois
  • +87 more
Jan 20, 2023

Ponatinib in CML Patients in Chronic Phase

Recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • Therapeutic drug monitoring
  • Molecular Response
  • Cagliari, Italy
  • +4 more
Nov 3, 2023

3L+ Therapies Among Chronic Myeloid Leukemia and Those With

Completed
  • Chronic Myeloid Leukemia
    • East Hanover, New Jersey
      Novartis Investigative Site
    Nov 11, 2022

    Philadelphia Chromosome Positive CML, BCR-ABL Positive Chronic Myelogenous Leukemia Trial in France (Ponatinib, Imatinib)

    Recruiting
    • Philadelphia Chromosome Positive CML
    • BCR-ABL Positive Chronic Myelogenous Leukemia
    • Amiens, France
    • +27 more
    Dec 9, 2021

    B Acute Lymphoblastic Leukemia Trial (procedure, biological, drug, radiation)

    Not yet recruiting
    • B Acute Lymphoblastic Leukemia
    • Biospecimen Collection
    • +19 more
    • (no location specified)
    Nov 8, 2023

    Chronic Myeloid Leukemia Trial in New York (Nilotinib)

    Completed
    Has Results
    • Chronic Myeloid Leukemia
    • New York, New York
      Weill Cornell Medical College
    Mar 24, 2022

    Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) Trial in Tokyo (Nilotinib)

    Completed
    • Chronic Myelogenous Leukemia
    • Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
    • Tokyo, Japan
      Novartis Investigative Site
    Dec 6, 2020

    Chronic Myelogenous Leukemia Trial in Worldwide (Dasatinib)

    Active, not recruiting
    • Chronic Myelogenous Leukemia
    • Amman, Jordan
    • +4 more
    Jan 17, 2022

    Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

    Recruiting
    • Chronic Phase Chronic Myelogenous Leukemia
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 11, 2022

    Accelerated Phase Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Phase

    Terminated
    • Accelerated Phase Chronic Myelogenous Leukemia (CML)
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Nov 17, 2020

    Chronyc Myeloid Leukemia Trial in Italy, Netherlands (Imatinib, Nilotinib)

    Active, not recruiting
    • Chronyc Myeloid Leukemia
    • Alessandria, Italy
    • +81 more
    Jan 4, 2022

    Chronic Myeloid Leukemia Trial in Worldwide

    Recruiting
    • Chronic Myeloid Leukemia
      • MontrĂ©al, Quebec, Canada
      • +25 more
      Jul 25, 2022

      Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia Trial in Aichi (Nilotinib)

      Completed
      • Chronic Myelogenous Leukemia
      • Acute Lymphoblastic Leukemia
      • Aichi, Japan
        Novartis Investigative Site
      Dec 6, 2020

      Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid Trial in Augusta, Milwaukee (Asciminib, Ascimininb +

      Recruiting
      • Chronic Myeloid Leukemia, Chronic Phase
      • +3 more
      • Augusta, Georgia
      • +1 more
      Jul 14, 2022

      Chronic Myelogenous Leukemia - Chronic Phase Trial (asciminib)

      Recruiting
      • Chronic Myelogenous Leukemia - Chronic Phase
      • Birmingham, Alabama
      • +25 more
      Jan 10, 2023

      Describe Real World Use of Bosutinib inSingle Centre in Scotland

      Completed
      • Myeloid Leukemia
      • Glasgow, United Kingdom
        eatson West of Scotland Cancer Centre
      May 3, 2022

      BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib

      Active, not recruiting
      • Chronic Myeloid Leukemia
      • Dasatinib discontinuation
      • Rionero in Vulture, Potenza, Italy
      • +36 more
      Jan 4, 2022

      Chronic Phase Chronic Myeloid Leukemia Trial in Bruxelles (Ponatinib 30 mg QD, Ponatinib 15 mg QD, Nilotinib 400 mg BID)

      Terminated
      Has Results
      • Chronic Phase Chronic Myeloid Leukemia
      • Ponatinib 30 mg QD
      • +2 more
      • Bruxelles, Belgium
        Cliniques Universitaire Saint-Luc (Site 058)
      Oct 28, 2021

      Chronic Myeloid Leukemia Trial in Worldwide (nilotinib)

      Active, not recruiting
      Has Results
      • Chronic Myeloid Leukemia
      • Los Angeles, California
      • +61 more
      Mar 17, 2022

      CML Any Phase of the Disease Treated With Ponatinib (Iclusig®)

      Active, not recruiting
      • Chronic Myeloid Leukemia
        • Saint-Pierre, Reunion, France
        • +39 more
        Dec 13, 2021

        Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Houston (BP1001 (varying

        Withdrawn
        • Chronic Myelogenous Leukemia, Ph1-Positive
        • +2 more
        • BP1001 (varying dose)
        • +2 more
        • Houston, Texas
          The University of Texas M.D. Anderson Cancer Center
        May 26, 2020

        Prophylactic HQP1351 Therapy, Third Generation TKI Trial in Guanzhou (HQP1351( Olverembatinib dimesylate))

        Withdrawn
        • Prophylactic HQP1351 Therapy
        • Third Generation TKI
        • HQP1351( Olverembatinib dimesylate)
        • Guanzhou, China
          Department of Hematology, Nanfang Hospital, Southern Medical Uni
        Jan 16, 2023